Alnylam Pharmace. buy StockNews.com
Summary
This prediction ended on 23.07.24 with a price of €217.60. The BUY prediction by StockNews_com finished with a performance of 15.62%. StockNews_com has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. StockNews_com has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Alnylam Pharmace. | -9.541% | -9.541% | 22.849% |
iShares Core DAX® | -1.215% | 4.788% | 16.604% |
iShares Nasdaq 100 | -1.911% | 1.109% | 19.364% |
iShares Nikkei 225® | -3.171% | 5.626% | 10.519% |
iShares S&P 500 | -1.029% | 1.792% | 20.514% |
Comments by StockNews_com for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.